Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the second quarter ended June 30, 2009.

"We were pleased to observe continued sales growth in our Proprietary Medical Products business during the quarter, including continued acceleration of our important Quill(TM) SRS and HemoStream(TM) product lines," said Dr. William Hunter, President and CEO of Angiotech. "Despite the continued challenges we are experiencing in certain parts of our Base Medical Products business, the continued stabilization of our TAXUS(R)-derived royalty revenue, the possibility that Cook's Zilver(TM) paclitaxel-eluting peripheral stent may contribute additional royalty revenue and the recent FDA approval of our Option(TM) Inferior Vena Cava Filter leave us optimistic about the second half of 2009 and 2010."

    Second Quarter Financial Highlights

    -   Total revenue was $64.6 million.

    -   Net product sales were $47.2 million. Sales of our Proprietary
        Medical Products were $13.5 million, or 29% of total product sales.
        Sales of our Base Medical Products were $33.7 million, or 71% of
        total product sales.

    -   Royalty revenue was $17.0 million.

    -   Adjusted EBITDA (earnings before interest, taxes, depreciation and
        amortization, adjusted to exclude certain non-cash and non-recurring
        items) was $12.6 million.

    -   Research and development expenses were $6.8 million, and as adjusted
        to exclude non-cash stock-based compensation expenses and other non-
        recurring costs were $6.1 million.

    -   Selling, general and administrative expenses were $21.6 million, and
        as adjusted to exclude non-cash stock-based compensation expenses,
        certain litigation costs, non-recurring fi
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... woundcare division of,Insense Ltd., today announced it has received ... Oxyzyme product in the treatment of,difficult and chronic wounds. ... one of the world,s leading wound care specialists, in ... The announcement was made at,the 3rd Congress of the ...
... June 6 Inverness Medical,Innovations, Inc. (Amex: IMA ... for the consumer and professional markets, today,announced that it ... & Medical Technology Conference being held June 11-12, 2008,at ... Jon Russell, Vice President,Finance, will present on Thursday, June ...
... June 6 DURECT Corporation,(Nasdaq: DRRX ) announced today that ... New York, NY., -- Needham & Company,s ... June 12th at 11:30 a.m. EDT. -- Leerink Swann,s Pain ... 12:45 p.m. EDT. -- Jefferies, 2nd Annual Healthcare Conference on ...
Cached Biology Technology:Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada 2
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... study sheds additional light on how erectile dysfunction (ED) ... uncovering the link between the two disorders, and may ... study, "Lack of Central Nitric Oxide Triggers Erectile Dysfunction ... Mayhan, and Kaushik P. Patel, Departments of Cellular and ...
... therapy in mice to shut down a gene that plays ... , The technique, detailed in an upcoming issue of Vision ... material called interfering RNA, which helps disable the gene. ... mutated versions of it are passed from generation to generation ...
... made his way out of Africa some 60,000 years ... He was accompanied by the bacterium Helicobacter pylori, which ... the bacterium spread throughout the entire world. This is ... led by Mark Achtman from the Max Planck Institute ...
Cached Biology News:Erectile dysfunction in diabetes is due to selective defect in the brain 2Erectile dysfunction in diabetes is due to selective defect in the brain 3Gene therapy for blindness clears hurdle in mice 2Out of Africa -- Bacteria, as well 2
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
...
... MW: 34.2kDa Formulation: 10mM HEPES, pH ... dithiothreitiol with 50% glycerol Properites: For ... Certificate of Analysis for individual lots ... followed by gel filtration and Mono-S ...
Antibody Purification Specificity: Antibody Purification ...
Biology Products: